Genmab

ProfoundBio is a clinical-stage biotechnology company dedicated to creating novel antibody-based therapeutics aimed at treating cancer. The company utilizes innovative proprietary technology platforms to develop a diverse pipeline of antibody-drug conjugate (ADC) candidates that target both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus on advancing targeted therapeutics leverages the immune system's capabilities to potentially eradicate cancer, offering improved treatment options with curative potential for patients.

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. Utilizing its proprietary Boltbody platform, the company creates immune-stimulating antibody conjugates (ISAC) that link tumor-targeting antibodies with potent immune stimulants. This approach aims to transform cold tumors into immunologically active ones, enhancing the body’s ability to eliminate cancer. Bolt Biotherapeutics is advancing several candidates in its pipeline, including BDC-1001, which is being developed as a monotherapy for patients with HER2-expressing solid tumors. With a strong emphasis on myeloid biology and cancer drug development, the company is dedicated to harnessing both innate and adaptive immune responses to improve cancer treatment outcomes. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics continues to push the boundaries of immuno-oncology.